Natasha Kekre profile picture

Contact Information

Natasha Kekre, BSc, MD, MPH, FRCPC
6137378899 x.71064
nkekre@toh.ca

501 Smyth Road
CPCR Box 201A
Ottawa, ON
K1H 8L6

ORCID logo https://orcid.org/0000-0001-8394-0855

Publications

Selected Publications

Castillo G, Lalu M, Asad S, Foster M, Kekre N, Fergusson D, Hawrysh T, Atkins H, Thavorn K, Montroy J, Schwartz S, Holt R, Broady R, Presseau J. Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. Trials. 2021 Mar 25;22(1):230.

Khalife R, Montroy J, Grigor E, Fergusson DA, Atkins H, Seftel M, Presseau J, Thavorn K, Holt RA, Hay K, Lalu MM, Kekre N. Building Canadian Capacity for CAR-T cells in Relapsed/Refractory Acute Lymphoblastic Leukemia: A retrospective cohort study. British Journal of Hematology. Br J Haematol 2020 Oct;191(1):e14-e19.

Kekre N, Kim HT, Hofer JH, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Phase II Trial of Natalizumab with Corticosteroids as Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease. Bone Marrow Transplant. 2020 Sep 8. doi: 10.1038/s41409-020-01049-0.

Heelan F, Mallick R, Adam Bryant A, Radhwi O, Atkins H, Huebsch L, Bredeson C, Allan D, Kekre N. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation? Biol Blood Marrow Transplant. 2020 Jul;26(7):1298-1302.

Grigor ELM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel M, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, and Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 Apr;33(2):98-110.

All Other Publications

1. Maganti HB, Kirkham AM, Bailey AJM, Shorr R, Kekre N, Pineault N, Allan DS. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: a systematic review and meta-analysis of preclinical studies . Cytotherapy (accepted Oct 24, 2021).

2. Wilson M, Thavorn K, Hawrysh T, Graham ID, Atkins H, Kekre N, Coyle D, Lalu MM, Fergusson DA, Chan KK, Ollendorf DA and Presseau J. Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. BMJ Open 2021;0:e046707. doi:10.1136/bmjopen-2020-046707 (accepted July 20, 2021).

3. Bastin DJ, Khan ST, Montroy J, Kennedy MA, Forbes N, Martel AB, Baker L, Gresham L, Boucher DM, Wong B, Shorr R, Diallo JS, Fergusson DA, Lalu MM, Auer RC, Kekre N. Safety and Efficacy of Autologous Whole Cell Vaccines in Hematologic Malignancies: A Systematic Review and Meta-analysis. Hematological Oncology (accepted Apr 26, 2021).

4. Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Jul 22;138(3):273-282.

5. Castillo G, Lalu M, Asad S, Foster M, Kekre N, Fergusson D, Hawrysh T, Atkins H, Thavorn K, Montroy J, Schwartz S, Holt R, Broady R, Presseau J. Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. Trials. 2021 Mar 25;22(1):230.

6. Chruscinski A, Moshkelgosha S, Juvet S, Grant D, Renner E, Bredeson C, Macarthur M, Clement AM, Allan D, Altouri S, Bence-Bruckler I, Fulcher J, Huebsch L, Kew A, Kekre N, Sabloff M, McDiarmid S, Martin L, Lilly L, Selzner N, Galvin Z, Adeyi O, Fisher S, Zhang J, Epstein M, Yi TJ, Cattral M, McGilvray I, Ghanekar A, Selzner M, Greig P, Kim TK, Khalili K, Tinckham K, Humar A, Demetris AJ, Levy G, Atkins H. Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients with Recurrent Primary Sclerosing Cholangitis: A Pilot Study. Transplantation. 2021, in press (accepted Mar 25, 2021).

7. Castillo G, Lalu, MM, Asad S, Foster M, Kekre N, Fergusson D, Hawrysh T, Atkins H, Thavorn K, Montroy J, Schwartz S, Holt RA, Broady R, Presseau J. Navigating choice in the face of uncertainty: Using a theory informed qualitative approach to identifying potential barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial. 2021. BMJ Open, 11: e043929. http://dx.doi.org/10.1136/bmjopen-2020-043929

8. Masson-Roy J, Breiner A, Warman J, Pringle CE, Allan D, Bredeson C, Huebsch L, Kekre N, Kennah ML, Martin L, McDiarmid S, Altouri S, Atkins H, Bourque PR. Autologous hematopoietic stem cell transplantation for refractory typical CIDP and Lewis- Sumner syndrome. The Canadian Journal of Neurological Sciences. 2021, in press (accepted Feb 8, 2021).

9. Bejanyan N, Zhang M, Bo-Subait K, … Kekre N, … Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC compared to RIC HCT in AML/MDS with low/intermediate risk DRI. Transplant Cell Ther. 2021 Jan;27(1):68.e1-68.e9. doi: 10.1016/j.bbmt.2020.09.026.

10. Sterrett R, Figueiredo A, Mallick R, Kekre N, Atkins H, McCurdy A. Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation – A Retrospective Analysis. Hematol Transfus Cell Ther. 2020 Sep 13; S2531-1379(20).

11. Foster M, Fergusson D, Hawrysh T, Presseau J, Kekre N, Schwartz S, Castillo G, Asad S, Fox G, Atkins H, Thavorn K, Montroy J, Holt R, Monfaredi Z, Lalu M. Partnering with Patients to Get Better Outcomes with Chimeric Antigen Receptor T-cell Therapy: Towards Engagement of Patients in Early Phase Trials. Res Involv Engagem. 2020 Oct 14; 6:61.

12. Khalife R, Montroy J, Grigor E, Fergusson DA, Atkins H, Seftel M, Presseau J, Thavorn K, Holt RA, Hay K, Lalu MM, Kekre N. Building Canadian Capacity for CAR-T cells in Relapsed/Refractory Acute Lymphoblastic Leukemia: A retrospective cohort study. British Journal of Hematology. Br J Haematol 2020 Oct;191(1):e14-e19.

13. Kekre N, Kim HT, Hofer JH, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Phase II Trial of Natalizumab with Corticosteroids as Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease. Bone Marrow Transplant. 2020 Sep 8. doi: 10.1038/s41409-020-01049-0.

14. Heelan F, Mallick R, Adam Bryant A, Radhwi O, Atkins H, Huebsch L, Bredeson C, Allan D, Kekre N. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation? Biol Blood Marrow Transplant. 2020 Jul;26(7):1298-1302.

15. Zhou Z, Nath R, Cerny J, …Kekre N, …Saber W. Reduced Intensity Conditioning for Acute Myeloid Leukemia using Melphalan versus Busulfan based Regimens – A CIBMTR Report. Blood Advances. 2020 Jul 14;4(13):3180-3190.

16. Sabloff M, Altouri S, Allan D, Atkins H, Fulcher J, Huebsch L, Kekre N, Maze D, Ramsay T, Samant R, and Bredeson C. Total Body Irradiation (18Gy) Without Chemotherapy as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Refractory Acute Myeloid Leukemia. Bone Marrow Transplant. 2020 Jul;55(7):1454-1456.

17. Dreolini L, Cullen M, Yung E, Laird L, Webb JR, Nelson BH, Hay KA, Balasundaram M, Kekre N, Holt RA. A Rapid and Sensitive Nucleic Acid Amplification Technique for Mycoplasma Screening of Cell Therapy Products. Mol Ther Methods Clin Dev. 2020 Jun 12; 17: 393–399.

18. Khan ST, Montroy J, Forbes N, Bastin D, Kennedy MA, Diallo JS, Kekre N, Fergusson DA, Lalu M, Auer RC. Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. BMJ Open. 2020 Jun 8;10(6):e034714.

19. Figueiredo A, Atkins H, Mallick R, Kekre N, Kew A, McCurdy A. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma. Curr Oncol. Apr 2020;27(2):e81-e85.

20. Cheung J, Wentzell J, Trinacty M, Giguere P, Patel P, Kekre N, Nguyen T. Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice. Can J Hosp Pharm. 2020 Jan-Feb;73(1):37-44.

21. Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical Donor? Haematologica. 2020 Feb; 105(2): 407–413.

22. Lebo NL, Quimby AE, Caulley L, Thavorn K, Kekre N, Brode S, Johnson-Obaseki S. Surgical site infection affects length of stay and cost after complex head and neck procedures. Laryngoscope. 2020 Jan 24. doi: 10.1002/lary.28512.

23. Bejanyan N, Kim S, Hebert K, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy S, Beitinjaneh A, Boelens J, Diaz MA, Dvorak C, Gadalla S, Gajewski J, Gale R, Ganguly S, Gennery A, George B, Gergis U, Gomez-Almaguer D, Vincent MG, Hashem H, Kamble R, Kasow K, Lazarus H, Mathews V, Orchard P, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey A, Saldaña BD, Savani B, Winiarski K, Yared J, Weisdorf D, Antin J, and Eapen M. Choice of Conditioning Regimens for Bone Marrow Transplantation in Severe Aplastic Anemia. Blood Advances 2019 Oct 22, 3(20):3123-3131.

24. Sabloff M, Chhabra S*, Wang T, Fretham C, Kekre N, Abraham A, Adekola K, Auletta JJ, Barker C, Beitinjaneh A, Bredeson C, Bufarull RM, Cahn J, Diaz MA, Freytes C, Gale RP, Ganguly S, Gergis U, Guinan E, Hamilton B, Hashmi S, Hematti P, Hildebrandt G, Holmberg L, Hong S, Lazarus H, Muffly L, Nishihori T, Perales MA, Yared J, Mineishi S, Stadtmauer EA, Pasquini MC, Loren AW. Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation. Biol Blood Marrow Transplant 2019 Dec, 25(12):2398-2407.

25. Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea III EP, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplant. Blood Advances. 2019 Jul 23; 3(14):2199-2204.

26. Figueiredo A, Kassis R, Albacker R, McCurdy A, Kekre N, Atkins H. The Impact of Multiple Myeloma Induction Therapy on Hematopoietic Stem Cell Mobilization and Collection: 25-Year Experience. Hematol Transfus Cell Ther. 2019 Oct-Dec; 41(4):285-291.

27. Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo JS, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C, Lalu MM. Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. Mol Ther Oncolytics. 2019 Sep 27; 14: 179–187.

28. Grigor ELM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel M, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, and Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 Apr;33(2):98-110.

29. Li T, Mallick R, McCurdy A, Mulpuru S, Huebsch L, Bredeson C, Allan D, Kekre N. Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):68-72.

30. Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019 Jan; 33:24-32.

31. Visram A, Aziz J, Bryant A, Zhang T, Cieniak C, Hamelin L, Landry C, Morris G, Mercer D, Atkins H, Huebsch L, Al-Touri S, Fulcher J, Sabloff M, Kekre N, Bredeson C, Allan D. Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. Biol Blood Marrow Transplant. 2018 Dec;24(12):2466-2470.

32. Angka L, Martel AB, Kilgour M, Jeong A, Sadiq M, de Souza CT, Baker L, Kennedy MA, Kekre N, Auer RC. Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. Ann Surg Oncol. 2018 Sep 05: 1-8.

33. Visram A, Bredeson C, Allan D, Sabloff M, Huebsch L, Tay J, Kekre N, McDiarmid S, Mallick R, Tinmouth A, Martin L, Hamelin L, Maze D. Long-Term Graft Function in Predicted Poor Mobilizers Following Autologous Hematopoietic Cell Transplantation and the Impact of Preemptive Plerixafor. Blood Cancer J. 2018 Jan 29;8(1):14.

34. Grigor EJM, Fergusson D, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM. Efficacy and safety of Chimeric Antigen Receptor T-cell (CAR-T) therapy in patients with hematologic and solid malignancies: protocol for a systemic review and meta-analysis. BMJ Open. 2017 Dec 29;7(12):e019321.

35. Bryant, A, Mallick, R, Huebsch L, Allan D, Atkins H, Anstee G, Sabloff M, Scrivens N, Maze D, Bredeson C, and Kekre N. Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 2017. Dec;23(12):2096-2101.

36. Kekre, N, Antin, J.H. ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Advances. 2017 Mar;1(9):573-576.

37. Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 Jul;102(7):1185-1191.

38. Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P, Atta EH, Ayas M, Boelens JJ, Bonfim C, Deeg HJ, Kapoor N, Lee JW, Nakamura R, Pulsipher MA, Eapen M, Antin JH. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017Jul;102(7):1291-1298.

39. Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana JL, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Corral LL, Solano C, Armand P and Perez-Simon JA. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients undergoing Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-15.

40. Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Brånvall E, Cutler CS. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol. 2016 Jun;91(6):551-5.

41. Kekre N, Antin JH. Emerging drugs for graft-versus-host disease. Expert Opin Emerg Drugs. 2016 Jun;21(2):209-18.

42. Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent GVHD: a scoping review of the evidence. Biol Blood Marrow Transplant. 2016 Aug;22(8):1416-23.

43. Kekre N, Antin JH. Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol. 2016 Apr;53(2):98-102.

44. Martin PS, Li S, Nikiforow S, Alyea EP 3rd, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr;101(4):499-505.

45. Kekre N, Ho VT. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis and Chronic Myelomonocytic Leukemia. Am J Hematol. 2016 Jan;91(1):123-30.

46. Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression taper in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep;100(9):1222-7.

47. Kekre N, Koreth J. Novel Strategies to Prevent Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Curr Opin Hematol. 2015 Mar;22(2):116-22.

48. Christou G, Kekre N, Petrcich W, Tokessy M, Neurath D, Giulivi A, Saidenberg E, McDiarmid S, Atkins H, Bence-Bruckler I, Bredeson C, Huebsch L, Sabloff M, Sheppard D, Tay J, Tinmouth A, Allan DS. Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. Transfusion. 2015 Feb;55(2):253-8.

49. Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014 Jul 17;124(3):334-43.

50. Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, Allan D,Tay J, Tinmouth A, Sheppard D. Is CMV testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant. 2013 Dec;19(12):1719-24.

51. Kekre N, Mallick R, Allan D, Tinmouth A, Tay J. The impact of prolonged storage of red blood cells on cancer survival. PLoS One. 2013 Jul 16;8(7):e68820.

52. Fralick M, Bouganim N, Kremer R, Kekre N, Robertson S, Vandermeer L, Kuchuk I, Li J, Murshed M, Clemons M. Histomorphometric and microarchitectural analyses using the 2mm bone marrow trephine in metastatic breast cancer patients - preliminary results. Journal of Bone Oncology. 2012; 1: 69-73.

53. Kekre N, Philippe J, Mallick R, Smith S, Allan D. Modeling improvements in cell yield of banked umbilical cord blood and the impact on availability of donor units for transplantation into adults. Stem Cells Int. 2013; 2013:124834.

54. Kekre N, Christou G, Mallick R, Tokessy M, Tinmouth A, Tay J, Allan DS. Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. Transfusion. 2012 Sep;52(9):2049-54.

55. Kekre N, Djordjevic B, Touchie C. Spontaneous tumour lysis syndrome. CMAJ. 2012 May 15;184(8):913-6.2.

56. Kekre N, Chou A, Tokessey M, Doucette S, Tinmouth A, Tay J, Allan DS. Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation. Transfusion. 2011 Nov; 51(11): 2488-94.

57. Rodger MA, Kekre N, Le Gal G, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Betancourt MT, Kovacs MJ. Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism. Br J Haematol. 2011 Nov; 155(4):511-3.

58. Kekre N, Griffin C, McNulty J, Pandey S. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemother Pharmacol. 2005 Jul;56(1):29-38.

59. Pandey S, Kekre N, Naderi J, McNulty J. Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artif Cells Blood Substit Immobil Biotechnol. 2005; 33(3):279-95.

60. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis. 2005 May;10(3):619-30.

Listings from The Ottawa Hospital Library

This lists the 20 most recent publications in The Ottawa Hospital's Library database from this researcher.This database only starts tracking a researcher's publications once they start working at the Ottawa Hospital Research Institute.

Kekre, N; Kim, HT; Hofer, J; Ho, VT; Koreth, J; Armand, P; Nikiforow, S; Gooptu, M; Romee, R; Alyea, EP; Nageshwar, P; Glotzbecker, B; El-Jawahri, A; DeFilipp, Z; Soiffer, RJ; Antin, JH; Chen, YB; Cutler, C, 2021, Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease, BONE MARROW TRANSPLANTATION, 56, 5, 1006-1012 ➤ view abstract

Castillo, G; Lalu, MM; Asad, S; Foster, M; Kekre, N; Fergusson, DA; Hawrysh, T; Atkins, H; Thavorn, K; Montroy, J; Schwartz, S; Holt, RA; Broady, R; Presseau, J, 2021, Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial, BMJ OPEN, 11, 3 ➤ view abstract

Wilson, M; Thavorn, K; Hawrysh, T; Graham, ID; Atkins, H; Kekre, N; Coyle, D; Lalu, MM; Fergusson, DA; Chan, KKW; Ollendorf, DA; Presseau, J, 2021, Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor, BMJ OPEN, 11, 8 ➤ view abstract

Castillo, G; Lalu, M; Asad, S; Foster, M; Kekre, N; Fergusson, D; Hawrysh, T; Atkins, H; Thavorn, K; Montroy, J; Schwartz, S; Holt, R; Broady, R; Presseau, J, 2021, Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study, TRIALS, 22, 1 ➤ view abstract

Neelapu, SS; Dickinson, M; Munoz, J; Ulrickson, ML; Oluwole, OO; Herrera, AF; Thieblemont, C; Ujjani, CS; Lin, Y; Riedell, PA; Kekre, N; De Vos, S; Yang, Y; Milletti, F; Goyal, L; Kawashima, J; Chavez, JC, 2021, Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel as first-line therapy in patients with high-risk large B-cell lymphoma, BRITISH JOURNAL OF HAEMATOLOGY, 193, 36-37

Beltran-Bless, A; Murshed, M; Zakikhani, M; Kuchuk, I; Bouganim, N; Robertson, S; Kekre, N; Vandermeer, L; Li, J; Addison, CL; Rauch, F; Clemons, M; Kremer, R, 2021, Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients, BONE REPORTS, 15 ➤ view abstract

Gooptu, M; Romee, R; St Martin, A; Arora, M; Al Malki, M; Antin, JH; Bredeson, CN; Brunstein, CG; Chhabra, S; Fuchs, EJ; Ghosh, N; Grunwald, MR; Kanakry, CG; Kekre, N; McGuirk, JP; McNiece, IK; Mehta, RS; Mielcarek, M; Milano, F; Modi, D; Reshef, R; Solom, 2021, HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis, BLOOD, 138, 3, 273-282 ➤ view abstract

Bastin, DJ; Khan, ST; Montroy, J; Kennedy, MA; Forbes, N; Martel, AB; Baker, L; Gresham, L; Boucher, DM; Wong, B; Shorr, R; Diallo, JS; Fergusson, DA; Lalu, MM; Auer, RC; Kekre, N, 2021, Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis, HEMATOLOGICAL ONCOLOGY, 39, 4, 448-464 ➤ view abstract

Sterrett, R; Figueiredo, A; Mallick, R; Kekre, N; Atkins, H; McCurdy, A, 2021, Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis, HEMATOLOGY TRANSFUSION AND CELL THERAPY, 43, 4, 437-442 ➤ view abstract

Masson-Roy, J; Breiner, A; Warman-Chardon, J; Pringle, CE; Allan, D; Bredeson, C; Huebsch, L; Kekre, N; Kennah, ML; Martin, L; McDiarmid, S; Altouri, S; Atkins, H; Bourque, PR, 2021, Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 48, 6, 760-766 ➤ view abstract

Figueiredo, A; Atkins, H; Mallick, R; Kekre, N; Kew, A; McCurdy, A, 2020, Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma, CURRENT ONCOLOGY, 27, 2 ➤ view abstract

Dreolini, L; Cullen, M; Yung, E; Laird, L; Webb, JR; Nelson, BH; Hay, KA; Balasundaram, M; Kekre, N; Holt, RA, 2020, A Rapid and Sensitive Nucleic Acid Amplification Technique for Mycoplasma Screening of Cell Therapy Products, MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 17, 393-399 ➤ view abstract

Heelan, F; Mallick, R; Bryant, A; Radhwi, O; Atkins, H; Huebsch, L; Bredeson, C; Allan, D; Kekre, N, 2020, Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26, 7, 1298-1302 ➤ view abstract

Khalife, R; Montroy, J; Grigor, EJM; Fergusson, DA; Atkins, H; Seftel, M; Presseau, J; Thavorn, K; Holt, RA; Hay, K; Lalu, MM; Kekre, N, 2020, Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study, BRITISH JOURNAL OF HAEMATOLOGY, 191, 1

Khan, ST; Montroy, J; Forbes, N; Bastin, D; Kennedy, MA; Diallo, JS; Kekre, N; Fergusson, DA; Lalu, M; Auer, RC, 2020, Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews, BMJ OPEN, 10, 6 ➤ view abstract

Cheung, J; Wentzell, J; Trinacty, M; Giguere, P; Patel, P; Kekre, N; Nguyen, T, 2020, Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice, CANADIAN JOURNAL OF HOSPITAL PHARMACY, 73, 1, 37-44 ➤ view abstract

Lebo, NL; Quimby, AE; Caulley, L; Thavorn, K; Kekre, N; Brode, S; Johnson-Obaseki, S, 2020, Surgical Site Infection Affects Length of Stay After Complex Head and Neck Procedures, LARYNGOSCOPE, 130, 12 ➤ view abstract

Altouri, S; Allan, D; Atkins, H; Fulcher, J; Huebsch, L; Kekre, N; Maze, D; Ramsay, T; Samant, R; Bredeson, C; Sabloff, M, 2020, Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia, BONE MARROW TRANSPLANTATION, 55, 7, 1454-1456

Perales, MA; Tomlinson, B; Zhang, MJ; St Martin, A; Beitinjaneh, A; Gibson, J; Hogan, W; Kekre, N; Lazarus, H; Marks, D; McGuirk, J; Romee, R; Solh, M; Wagner, JE; Weisdorf, DJ; de Lima, M; Eapen, M, 2020, Alternative donor transplantation for acute myeloid leukemia in patients aged >= 50 years: young HLA-matched unrelated or haploidentical donor?, HAEMATOLOGICA, 105, 2, 407-413 ➤ view abstract

Sobh, M; Huebsch, L; Sabloff, M; Fulcher, J; Altouri, S; Kennah, M; Drouin, E; Allan, D; Atkins, H; Christou, G; Villeneuve, P; Blanchard, AP; Maclellan, K; Mallick, R; Laferriere, N; Gopalakrishnan, SK; Bhella, SD; McDiarmid, SA; Kekre, N; Bredeson, C, 2020, Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26, 3

More publications may be available in The Ottawa Hospital Library database.